Drugs / LY4292009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06977880 | Feb 2025 → Mar 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4292009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06977880 ↗ |
| Known as | MORF-440 | “A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants” NCT06977880 ↗ |
| Route | Oral | “Administered orally” NCT06977880 ↗ |